CD19 and acute lymphoblastic leukemia: In CD19neg relapses, which account for around half of the cases (39% and 68% in respectively Gardner et al.9 and Maude et al.8 studies), leukemic cells lose CD19 epitope surface expression and thus escape CAR-mediated recognition, inhibiting B-ALL clearance.